Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.49 |
| ▸ | FAAH | O00519 | 4/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19417742 | 0.87 | HSD11B1 (0.42) | GHSRMTNR1AMTNR1BFAAHHSD11B1 | |
| SCHEMBL19277248 | 0.84 | GHSR (0.46) | GHSRMTNR1AMTNR1BFAAHP2RX7 | |
| SCHEMBL20909776 | 0.81 | ACHE (0.44) | GHSRFAAHHSD11B1 | |
| SCHEMBL15478536 | 0.80 | MTNR1A (0.57) | GHSRMTNR1AMTNR1BFAAHP2RX7 | |
| SCHEMBL406043 | 0.80 | MTNR1A (0.57) | GHSRMTNR1AMTNR1BFAAHP2RX7 | |
| SCHEMBL6427539 | 0.78 | FAAH (0.53) | GHSRMTNR1AMTNR1BFAAHP2RX7 | |
| SCHEMBL1193346 | 0.78 | FAAH (0.53) | GHSRMTNR1AMTNR1BFAAHP2RX7 | |
| SCHEMBL367535 | 0.78 | FAAH (0.53) | GHSRMTNR1AMTNR1BFAAHP2RX7 | |
| SCHEMBL5608206 | 0.78 | FAAH (0.53) | GHSRMTNR1AMTNR1BFAAHP2RX7 | |
| SCHEMBL6534185 | 0.78 | FAAH (0.53) | GHSRMTNR1AMTNR1BFAAHP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168966-B1 | BICYCLOANILINE DERIVATIVE | MSD KK (JP) | 2016-09-28 | — | — | EP | disclosed |
| EP-2168966-B1 | BICYCLOANILINE DERIVATIVE | MSD KK (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-8436004-B2 | Bicycloaniline derivative | MSD K.K. (JP) | 2013-05-07 | — | — | US | disclosed |
| US-8436004-B2 | Bicycloaniline derivative | MSD K.K. (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20110135601-A1 | BICYCLOANILINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. | 2011-06-09 | — | — | US | disclosed |
| US-20110135601-A1 | BICYCLOANILINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. | 2011-06-09 | — | — | US | disclosed |
| US-20110135601-A1 | BICYCLOANILINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. | 2011-06-09 | — | — | US | disclosed |
| EP-2168966-A1 | BICYCLOANILINE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-03-31 | — | — | EP | disclosed |
| EP-2168966-A1 | BICYCLOANILINE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135601-A1 | BICYCLOANILINE DERIVATIVE | WEE1, WEE2, CCNK | GHSR 3642/4885MTNR1A 1775/4885MTNR1B 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.